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1607-551X/Copyright ª 2015, KaohsiuAbstract Natural products have been widely reported as effective therapeutic alternatives
for treatment of depression. Sanyuansan is a compound recipe composed of ginseng total
saponins, fish oil, and valeriana. The aims of this study were to validate whether Sanyuansan
has antidepressant-like effects through acute behavioral tests including the forced swimming
test (FST), tail suspension test (TST), locomotor activity test, and chronic mild stress (CMS)
mice model of depression. C57BL/6 mice were given oral administration of 30 mg/kg imipra-
mine, Sanyuansan, and saline, respectively. The acute behavioral tests including the TST,
FST, and locomotor activity test were done after the administration of drugs for consecu-
tively three times (24 hours, 1 hour, and 0.5 hour prior to the tests). Furthermore, the
sucrose preference and the serum corticosterone level of mice in the CMS model were exam-
ined. Sanyuansan only at 900 mg/kg markedly reduced immobility time in the TST compared
with the saline-treated group of mice. Sanyuansan at doses of 225 mg/kg, 450 mg/kg, and
900 mg/kg significantly reduced immobility time of mice in the FST. Sanyuansan reversed
the CMS-induced anhedonia and hyperactivation of the hypothalamusepituitaryeadrenal
axis. In addition, our results showed that neither imipramine nor Sanyuansan at any dosage
increased spontaneous motor activity. These results suggested that Sanyuansan inducedeclare no conflicts of interest.
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606 S. Yan et al.significant antidepressant-like effects in mice in both acute and chronic animal models,
which seemed unlikely to be attributed to an increase in locomotor activities of mice, and
had no sedative-like effects.
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Depression is a major contributor to the global burden of
disease and disability. According to the World Health Or-
ganization survey, the relatively high lifetime prevalence of
depression ranges from 2% to 15% around the world [1]. It
costs $150 billion per year, according to the latest survey in
the United States [2]. Several physiological systems are
involved in the pathophysiology of depression, such as the
alteration of monoamine system, dysregulation of the
hypothalamusepituitaryeadrenal (HPA) axis, and imbal-
anced cytokine system [3e5]. So far, treatment of
depression entirely depends on antidepressants, which,
based on serendipitous findings made in the 1950s, act via
the monoamine neurotransmitters, such as serotonin or
noradrenaline. Only about 50% of patients show full
remission in response to these antidepressants [6]. Hence,
there is a pressing need for more effective and better
tolerated antidepressants.
Sanyuansan is a compound recipe composed of ginseng
total saponins (GTSs), fish oil, and valeriana, which is widely
used as a tonic food in China. In traditional Chinese medi-
cine, ginseng is used for treatment of various diseases of the
neuropsychological system, including mood disorders,
learning and memory deficit, and cerebral ischemia [7,8].
The major pharmacological active ingredients of ginseng are
triterpenoid saponins, which are responsible for its effects
on the central nervous system [9]. Omega-3 polyunsaturated
fatty acids are composed of alpha-linoleic acid, eicosa-
pentenoic acid, and docosahexenoic acid, mainly found in
fish oil. Several epidemiological investigations showed a
negative correlation between consumption of omega-3 fatty
acid and the prevalence and severity of depression. In
addition, recent clinical studies also provided evidence
about the benefits of omega-3 fatty acid in the treatment of
depressive disorders [10e13]. Omega-3 supplementation in
rodents’ diet exhibited antidepressant-like effects in
chronic studies [14,15], associated with an increase in the
hippocampal volume, an overexpression of brain-derived
neurotrophic factor, and an increase in the number of
newborn cells [16]. Valeriana is traditionally used for the
treatment of epilepsy, insomnia, neurosis, and sciatica [17].
In clinical investigations, extract of valeriana has been
shown to alleviate symptoms of depression [18]. Moreover, it
has been used in the treatment of anxiety and depression in
combination with other herbs [19e21].
In the present study, we investigated the
antidepressant-like effects of Sanyuansan in acute and
chronic mice models of depression.Materials and methods
Animals
All 137 male C57BL/6 mice weighing 18e22 g were pur-
chased from the Institute of Experimental Animals
(Chengdu, China). The animals were housed in groups under
controlled conditions (23.5  1.5C, under a 12-hour
lightedark cycle with lights on at 8:00 AM, food and water
provided ad libitum). The animals were allowed to adapt to
laboratory conditions for at least 1 week before the ex-
periments started. All experiments were performed during
the light phase of the lightedark cycle. All animal handling
procedures were performed in compliance with the Prin-
ciples of Laboratory Animal Care (NIH publication No. 80-
23, revised 1996) and the PR China legislation for the use
and care of laboratory animals. All possible steps were
taken to avoid animals’ suffering at any stage of the
experiments.Drug preparation and administration
Fish oil (25% omega-3) and imipramine (99%) were pur-
chased from SigmaeAldrich (St. Louis, MO, USA). GTSs was
purchased from Jilin University, and contained major gly-
cosides (Rg1 11.90%, Rb1 14.50%, Rb2 8.87%, Rc 11.25%, Rd
4.09%, and Re 3.17%) and other ginsenosides and compo-
nents (46.22%), and methanol extracts of valeriana (vale-
potriate, > 50%) were obtained from Wuhan Jianan Co.
(Wuhan, China). Sanyuansan was composed of GTSs,
omega-3, and valeriana in a ratio of 2:3:1 (w/w/w), sus-
pended with 0.1% carboxymethylcellulose.
In acute behavioral tests, animals were randomly
divided into five groups (n Z 21 per group) and orally
administered with imipramine (30 mg/kg), low dose
Sanyuansan (225 mg/kg), medium dose Sanyuansan
(450 mg/kg), high dose Sanyuansan (900 mg/kg), and saline,
respectively. These doses were chosen based on earlier
reports that GTSs, omega-3, valerian, and imipramine were
effective in producing physiological and behavioral effects
on rodents. All drugs and water were given at a volume of
20 mL/kg for three times at 24 hours, 1 hour, and 0.5 hour
prior to each behavioral test.
In the chronic mild stress (CMS) experiment, animals
were randomly divided into four groups (n Z 8 per group):
Control (saline), CMS þ Vehicle (CMS þ saline),
CMS þ Sanyuansan (CMS þ Sanyuansan 900 mg/kg), and
CMS þ IMI (CMS þ imipramine 30 mg/kg). These doses were
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drugs and water were given at a volume of 20 mL/kg once
per day during the CMS experiment.
Acute behavioral tests
We conducted three acute behavioral tests: the tail sus-
pension test (TST), the forced swimming test (FST), and the
locomotor activity measurement. These three tests were
each performed on seven mice of each drug/dose group.
TST
The TST was conducted as previously described by Steru
et al. [22]. Briefly, 30 minutes after the last drug adminis-
tration, animals were suspended by the tail from a ledge
with adhesive tape (approximately 1 cm from the tip of the
tail). The distance between the tip of the tail of the mouse
and the floor was approximately 30 cm. Each animal was
partitioned to avoid interference during the test. Immo-
bility was defined as the absence of movement for 6 mi-
nutes. Each mouse in the test was recorded by a
videocamera and scored by a blinded experimenter.
FST
The test was performed using the method described by
Porsolt et al. [23]. Briefly, 30 minutes after the last drug
administration, animals were placed in an open cylindrical
container (total volume, 2500 mL; height, 20 cm; diameter,
14 cm) filled with 10 cm of water (25C). Immobility was
defined as mouse ceasing struggling, remaining floating
motionless in water, and making only movements necessary
to keep its head above water. The duration of immobility in
the last 4 minutes of the (total) 6 minutes of swimming time
was recorded with a videocamera and scored by a blinded
experimenter.
Locomotor activity measurement
Locomotor activity was measured with a 36-point infrared
ray passive sensor system (model No. ZZ-6; Taimeng Tech
Ltd., Chengdu, Sichuan, China). Thirty minutes after the
last drug administration, animals were placed in a chamber
of locomotor activity measurement device to adjust to the
environment for 1 minute, then recorded and scored by
with infrared ray passive sensor system for 10 minutes.
CMS experiment protocol
The CMS procedure followed a fixed weekly schedule of
commonly used mild stressors such as cold water swimming
(4C, 5 minutes), overnight illumination (10 W LED, 15 Hz,
12 hours), wet cages (200mL water in sawdust bedding, 12
hours), cage tilt (keeping the cage tilted 45 without
bedding), restraint stress (2 hours), tailed clipped (5 mi-
nutes), empty water bottle (2 hours), and deprivation of
food and water (22 hours) with animals of the CMS group.
Single housed CMS mice received one stressor once per day
for 3 weeks consecutively.Sucrose preference test
The sucrose preference test was used to evaluate the
anhedonia state of CMS mice [24]. The test involved 22
hours of food and water deprivation, followed by presen-
tation of 2% sucrose and water for 2 hours. Intake was
measured by comparing the bottle weight prior to and after
the test [25]. The sucrose preference test was composed of
training and testing trials. The training test also served as
the baseline test prior to the start of the CMS protocol. The
testing trial was performed 24 hours after the 3-week CMS
protocol was completed. Sucrose preference index was
calculated as the ratio of the consumed sucrose solution to
the total amount of liquid consumed in 2 hours.
Determination of serum corticosterone level
Mice were anesthetized with sodium pentobarbital
(100 mg/kg, intraperitoneally), and cardiac blood was
collected just prior to sacrifice. Samples were centrifuged
for 15 minutes at 1300g within 30 minutes of collection and
were stored frozen (80C). Corticosterone (CORT) was
assayed in serum using an ELISA kit (Biovalue Inc., China)
Statistical analysis
Data were expressed as the mean  standard error of the
mean for the indicated analyses. Behavioral data were
analyzed using a one-way analysis of variance. Following
the analyses of variance, Dunnett’s post hoc tests were
used. For all analyses, a p value of <0.05 was considered
statistically significant.
Results
Effects of Sanyuansan on immobility time in TST
Sanyuansan at 900 mg/kg and imipramine at 30 mg/kg
markedly reduced immobility time compared with the sa-
line group [F(4, 30) Z 8.423, p < 0.01; Figure 1].
Post hoc analysis found that Sanyuansan at 900 mg/kg
(p < 0.05) decreased immobility time significantly less than
imipramine did (p < 0.01) in the TST, suggesting that
Sanyuansan was less sensitive than imipramine in the TST.
Sanyuansan at 900 mg/kg showed significant
antidepressant-like effects in the TST.
Effects of Sanyuansan on immobility time in FST
The effects of oral administration of Sanyuansan on
immobility time in the mouse FST are shown in Figure 2.
Sanyuansan (at 225 mg/kg, 450 mg/kg, and 900 mg/kg) and
imipramine (at 30 mg/kg) all significantly reduced immo-
bility time compared with saline-treated mice [F(4,
30) Z 4.984, p < 0.05].
Post hoc analysis found that imipramine (p < 0.01)
decreased immobility time but not as much as Sanyuansan
did (p < 0.01) in the FST, suggesting that Sanyuansan was
more sensitive than imipramine in the FST. Sanyuansan
exhibited a slight but insignificant dose-dependent decrease
Figure 1. Effects of drugs on immobility time in the tail suspension test (TST). The mice (7 for each group) were orally
administered saline, low dose Sanyuansan (225 mg/kg), medium dose Sanyuansan (450 mg/kg), high dose Sanyuansan (900 mg/kg),
and imipramine (30 mg/kg), respectively. The drugs were administered at 24 hours, 1 hour, and 0.5 hour prior to the TST. Results
are expressed as mean (SEM) of immobility time (in seconds). The differences were analyzed using one-way ANOVA followed by a
post hoc Dunnett’s test. For statistical significance, *p < 0.05 and **p < 0.01 when compared to the saline group. ANOVAZ analyses
of variance; SEM Z standard error of the mean.
Figure 2. Effects of drugs on immobility time in the forced swimming test (FST). The mice (7 for each group) were orally
administered saline, low dose Sanyuansan (225 mg/kg), medium dose Sanyuansan (450 mg/kg), high dose Sanyuansan (900 mg/kg),
and imipramine (30 mg/kg), respectively. The drugs were administered at 24 hours, 1 hour, and 0.5 hour prior to the FST. Results
are expressed as mean (SEM) of immobility time (in seconds). The differences were analyzed using one-way ANOVA followed by a
post hoc Dunnett’s test. For statistical significance, *p < 0.05 and **p < 0.01 when compared to the saline group. ANOVAZ analyses
of variance; SEM Z standard error of the mean.
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significant antidepressant-like effects in the FST.Effects of Sanyuansan on the locomotor activity
Treatments with Sanyuansan at 225 mg/kg, 450 mg/kg, and
900 mg/kg did not cause any significant difference in timeof either spontaneous activity or spontaneous standing
(Figure 3A and B). On the contrary, mice treated with
imipramine at 30 mg/kg showed markedly reduced time of
spontaneous activity [F(4,30) Z 4.255, p < 0.01] and
spontaneous standing [F(4,30)Z 3.457, p < 0.01; Figure 3A
and B]. The results indicated that Sanyuansan did not affect
the spontaneous activity of mice.
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mice
The effects of 3 weeks of oral administration of Sanyuansan
and imipramine on anhedonia in CMS mice are shown in
Figure 4 with the sucrose preference index. In the baseline
phase, the sucrose preference index did not differ signifi-
cantly among all the groups [F(3, 28) Z 0.993, p > 0.05;
data not shown]. After 3 weeks of CMS, significant differ-
ences were observed among the groups [F(3, 28)Z 32.526,
p < 0.01].
The post hoc results revealed that 3 weeks of CMS
significantly reduced mice sucrose preference (Control vs.Figure 3. Effects of drugs on locomotor activity. The mice (7
Sanyuansan (225 mg/kg), medium dose Sanyuansan (450 mg/kg), h
respectively. The drugs were administered at 24 hours, 1 hour, a
expressed as mean (SEM) of the times of (A) spontaneous activities
using one-way ANOVA followed by a post hoc Dunnett’s test. For s
group. ANOVA Z analyses of variance; SEM Z standard error of thCMS þ Vehicle), and oral administration of Sanyuansan at
900 mg/kg and imipramine at 30 mg/kg both significantly
ameliorated the sucrose preference reduction in CMS mice
compared with the CMS þ Vehicle group.
Effects of Sanyuansan on serum CORT level in CMS
mice
The effects of 3 weeks of oral administration of Sanyuansan
and imipramine on the serum CORT level in CMS mice are
shown in Figure 5. After 3 weeks of CMS treatment, sig-
nificant differences of CORT were noted among the groups
[F(3, 18) Z 11.638, p < 0.01].for each group) were orally administered saline, low dose
igh dose Sanyuansan (900 mg/kg), and imipramine (30 mg/kg),
nd 0.5 hour prior to the locomotor activity test. Results are
and (B) spontaneous standings. The differences were analyzed
tatistical significance, **p < 0.01 when compared to the saline
e mean.
Figure 4. Effects of drugs on sucrose preference in CMS mice (n Z 8). Results are expressed as mean (SEM) of sucrose pref-
erence index (%). The differences were analyzed using one-way ANOVA followed by a post hoc Dunnett’s test. For statistical
significance, **p < 0.01 when compared to the CMS þ Vehicle group. ANOVA Z analyses of variance; CMS Z chronic mild stress;
SEM Z standard error of the mean.
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treatment significantly elevated the mice serum CORT level
(Control vs. CMS þ Vehicle), and oral administration of
Sanyuansan at 900 mg/kg and imipramine at 30 mg/kg both
significantly reduced the serum CORT level in CMS mice
compared with the CMS þ Vehicle group.
Discussion
In the present study, we investigated the antidepressant-
like effects of Sanyuansan, composed of GTSs, omega-3,Figure 5. Effects of drugs on serum CORT level in CMS mice (nZ
(ng/mL). The differences were analyzed using one-way ANOVA foll
**p < 0.01 when compared to the CMS þ Vehicle group. AN
CORT Z corticosterone; SEM Z standard error of the mean.and valeriana, through acute mouse behavioral models of
despair tasks, TST and FST, which are well-established
screening paradigms for the antidepressants and CMS mice
model of depression, one of the most valuable and credible
rodent model to study depression in animals and mimicking
human depressive symptoms [24,26]. In the acute models,
Sanyuansan produced a significant reduction in immobility
time. In the CMS model, Sanyuansan reversed the anhe-
donia state and hyperactivation of the HPA axis induced by
CMS. These effects were comparable with that of the
reference antidepressant imipramine. Unlike imipramine,6). Results are expressed as mean (SEM) of serum CORT level
owed by a post hoc Dunnett’s test. For statistical significance,
OVA Z analyses of variance; CMS Z chronic mild stress;
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locomotor activity test. These results suggested that
Sanyuansan did have antidepressant-like effects, and its
antidepressant-like effects were of different pharmaco-
logic mechanism from that of imipramine.
The behavioral tests TST and FST are sensitive, believ-
able, and useful measurement in the evaluation of antide-
pressant drugs [22,23]. Both tests placed mice in an
inescapable situation, and the antidepressant-like activity is
expressed by the decrease in immobility duration. In our
study, oral administration of Sanyuansan and imipramine
showed different anti-immobility capacity in the TST and the
FST. In the TST, only Sanyuansan at 900 mg/kg significantly
decreased immobility time, although at a less effective level
than imipramine. In the FST, each dose of Sanyuansan
showed more anti-immobility capacity than imipramine.
These different behavioral results might be attributed to the
following factors. First, variability of the two animal models
in response to certain antidepressants indicates potentially
different pharmacological mechanisms mediating perfor-
mance in these tests [27]. Second, the spectrum of phar-
macological sensitivity of the two models is different. Detke
et al. [28] and Cryan et al. [29] reported that swimming
behavior in the FST is modulated by serotonergic neuro-
transmission, whereas climbing is mediated by norepineph-
rinergic neurotransmission. Norepinephrinergic drugs and
the mixed serotoninenoradrenaline reuptake inhibitor are
more effective than serotonin reuptake blockers in the TST
[30]. Moreover, imipramine induces a significant reduction
of immobility at lower doses in the TST (4 mg/kg) than in the
FST (30 mg/kg) [31]. Based on the different performance of
the two drugs between the TST and the FST, we speculated
that Sanyuansan might have different effects on the mono-
amine system compared with imipramine.
It has been reported that psychotonics, which are clin-
ically ineffective as antidepressants, also show anti-
immobility effects in the TST and FST by stimulants
[32,33]. In order to detect the possibility of a false positive
result in anti-immobility effects, we also performed a lo-
comotor activity test to the mice [22]. Our results showed
that neither imipramine nor Sanyuansan at any dosage
increased spontaneous activity, suggesting that the
antidepressant-like effects of Sanyuansan in the TST and
FST was unlikely to be attributed to the false positives. It is
of interest to note that imipramine significantly decreased
locomotor activities including times of spontaneous activity
and spontaneous standing, whereas Sanyuansan did not.
Several established antidepressants such as fluoxetine,
desipramine, and citalopram are reported to decrease the
locomotor activity, possibly because of their sedative ef-
fect [32,34,35].
The CMS model is considered to be the most valid and
reliable rodent model to study depression in animals and
mimicking human depressive symptoms [24,36]. Stress was
thought to be one of the key contributors to depression, so
the pattern that CMS induced depressive symptoms was
relevant to the causes of depression. According to the
Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition classification, presence of anhedonia, a key symp-
tom of depression, is a basis of depressive disorder di-
agnostics [37]. Therefore, we investigated the
antidepressant-like effects of oral administration ofSanyuansan in the CMS model. The results of the study were
in line with the previous finding [38] that chronic exposure
to mild stressors caused a decrease in the sucrose prefer-
ence index in mice, indicating the anhedonia state of mice.
Our result revealed that the anhedonia state induced by CMS
was normalized by oral administration of Sanyuansan at
900 mg/kg. Moreover, the effect of Sanyuansan was com-
parable to that of imipramine, suggesting that Sanyuansan
showed an antidepressant-like effect in the CMS model.
The HPA axis is one of the responders to stress. In the
face of persistent stress, continued activation of the HPA
axis could lead to a final common pathway, that is, failure
in maintaining homeostasis. Moreover, hypercortisolemia
had been one of the most reproducible biological findings in
major depression [39]. Therefore, we deteced the level of
serum CORT in CMS mice to assess the hypercortisolemia
state. Our results were consistent with the previous finding
that CMS elevated the serum CORT level in mice, indicating
hyperactivation in the HPA axis of CMS mice [40]. Further-
more, drug treatment showed that hyperactivation of the
HPA axis induced by CMS was reversed by Sanyuansan at
900 mg/kg and imipramine at 30 mg/kg.
Generally, Sanyuansan reduced immobility in the TST
and the FST but did not affect general locomotor activity in
acute behavioral tests and normalized anhedonia and
hyperactivation of the HPA axis in the CMS model, which
means that it has an antidepressant-like effect but is not
sedative.
In summary, Sanyuansan produced a significant antide-
pressant effect in acute and chronic mice models of depres-
sion. In contrast to imipramine, however, Sanyuansan did not
affect the spontaneous activities in the locomotor activity
test, suggesting that Sanyuansandid have antidepressant-like
effects, and its antidepressant-like effects involved a
different pharmacologicmechanism from that of imipramine.Acknowledgments
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